about
The evolution of poxvirus vaccinesDeletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-CDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu.Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizationsImproving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysVirological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.Ectopic expression of vaccinia virus E3 and K3 cannot rescue ectromelia virus replication in rabbit RK13 cellsSix host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse modelHead-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesSequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.Enhancing poxvirus vectors vaccine immunogenicity.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.Novel HIV vaccine strategies: overview and perspective.Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.Applications and challenges of multivalent recombinant vaccines.Clinical applications of attenuated MVA poxvirus strain.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciRecombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery.Meeting report VLPNPV: Session 5: Plant based technology.Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization.Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine.
P2860
Q26995905-FB9790F2-26B8-49DE-B228-8AA40D2B840AQ27306437-15EF4107-4F93-4050-823B-6DB8143C28F8Q30364312-ACFE8C2F-7A1B-4092-A75A-B4DA89750A38Q33602726-754837EE-7DF4-4192-92DA-85305FA5B0AAQ34593874-61A6EB30-2B52-4BCD-8384-F54A0C47569AQ34796206-B6D1A3CC-DA3A-4793-9637-497EC37670A8Q34991112-B44A633A-1BB7-4F6B-B0C6-E0F149E2A2ACQ35212666-A8971BA4-8DBA-4D0D-978F-15E6CFD5DBABQ35488175-1CB9861A-64D5-4EDA-932F-18284B5A90D6Q35570670-A8AFB636-688B-4808-805C-A6C4C7DB089BQ35685675-771966FC-51D3-485C-AAC2-AEC9795A9AE6Q35914311-423BA002-92F4-49CB-BFFE-653AEE4973F1Q36119504-ED842D34-2E46-4866-8320-F9ADD03AE776Q36625165-89B7AFED-F2B9-4ADA-AE21-C8356D9CA127Q36911682-70771A45-5E36-4A61-9AD6-4AE6DC52CBA0Q36978452-0FF2C1DF-A7E9-408A-ADD0-C1514AE6CDA6Q37643731-7F3BC254-B6B1-4CE8-A8DA-CA037B43C611Q37668399-CE9039F9-C922-4E7F-88D0-B06E69BEDE39Q37711813-8CF5A423-708F-4324-AC3A-238DAFB9AC1FQ38068270-28E213DC-F832-4A14-BBC3-B83604C74455Q38156198-288C1143-2724-4F8F-A7DB-71B212A72507Q38748193-C53D280C-BFBE-441B-853B-9A09E7EB6895Q40220988-5185CF26-0CBF-4463-A974-FECA96A21B08Q40235609-20947219-FA4C-4561-8D1F-F4A14404504DQ40339467-CF2FF97B-6AE6-486F-923B-74EEF1D58A84Q40384316-C6F027A4-A2C6-40AD-A0F2-4172272E56D9Q42346870-8A60A08F-2101-4541-9508-811E5356AF0AQ44569389-3BACBE76-3599-43B4-BF6B-2D10DF218404Q47252143-059B455E-F1B7-4462-9CF6-4FF0DD0B6112Q47375908-D49CBF07-F368-43D6-9189-18A9DB394ED0Q55397871-77F1C0E3-43EE-4A8E-B9E3-E7C042434801
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Poxvirus vectors as HIV/AIDS vaccines in humans
@ast
Poxvirus vectors as HIV/AIDS vaccines in humans
@en
Poxvirus vectors as HIV/AIDS vaccines in humans
@nl
type
label
Poxvirus vectors as HIV/AIDS vaccines in humans
@ast
Poxvirus vectors as HIV/AIDS vaccines in humans
@en
Poxvirus vectors as HIV/AIDS vaccines in humans
@nl
prefLabel
Poxvirus vectors as HIV/AIDS vaccines in humans
@ast
Poxvirus vectors as HIV/AIDS vaccines in humans
@en
Poxvirus vectors as HIV/AIDS vaccines in humans
@nl
P2093
P2860
P3181
P356
P1476
Poxvirus vectors as HIV/AIDS vaccines in humans
@en
P2093
Beatriz Perdiguero
Carmen Elena Gómez
Juan García-Arriaza
P2860
P304
P3181
P356
10.4161/HV.20778
P407
P577
2012-09-01T00:00:00Z